AU6219100A - The use of membranes, cells and tissue from the area postrema to identify therapeutic compounds - Google Patents

The use of membranes, cells and tissue from the area postrema to identify therapeutic compounds

Info

Publication number
AU6219100A
AU6219100A AU62191/00A AU6219100A AU6219100A AU 6219100 A AU6219100 A AU 6219100A AU 62191/00 A AU62191/00 A AU 62191/00A AU 6219100 A AU6219100 A AU 6219100A AU 6219100 A AU6219100 A AU 6219100A
Authority
AU
Australia
Prior art keywords
membranes
tissue
cells
therapeutic compounds
identify therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62191/00A
Other languages
English (en)
Inventor
Bronislava Gedulin
Andrew Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of AU6219100A publication Critical patent/AU6219100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU62191/00A 1999-07-13 2000-07-13 The use of membranes, cells and tissue from the area postrema to identify therapeutic compounds Abandoned AU6219100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14383099P 1999-07-13 1999-07-13
US60143830 1999-07-13
PCT/US2000/019497 WO2001033220A2 (en) 1999-07-13 2000-07-13 The use of the area postreama to identify therapeutic compounds

Publications (1)

Publication Number Publication Date
AU6219100A true AU6219100A (en) 2001-05-14

Family

ID=22505854

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62191/00A Abandoned AU6219100A (en) 1999-07-13 2000-07-13 The use of membranes, cells and tissue from the area postrema to identify therapeutic compounds

Country Status (4)

Country Link
EP (1) EP1194778A2 (ja)
JP (1) JP2003513281A (ja)
AU (1) AU6219100A (ja)
WO (1) WO2001033220A2 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002033514A2 (en) 2000-10-16 2002-04-25 Tradecard, Inc. Improved full service trade system
US7805359B2 (en) 2005-09-28 2010-09-28 Tradecard, Inc. Securitization of a commercial transaction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists

Also Published As

Publication number Publication date
WO2001033220A2 (en) 2001-05-10
WO2001033220A3 (en) 2001-10-25
EP1194778A2 (en) 2002-04-10
JP2003513281A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
AU4860900A (en) Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
AU2001288686A1 (en) Improved cardiac function through administration of es cells
AU2164101A (en) Fungicidal combinations of active substances
AU2002241520A1 (en) Blood assessment of injury
AU2001277521A1 (en) Diagnosis of diseases associated with cell signalling
AU7735200A (en) Treatment of tissue by application of energy and drugs
AU3813499A (en) The use of dihydropyrimidines as medicaments, and novel substances
AU3862900A (en) Porous tissue scaffolding materials and uses thereof
AU6246199A (en) Human interleukin-b50, therapeutic uses
AUPR074500A0 (en) Treatment of t cell disorders
AU2001285683A1 (en) Mild enrichment of foetal cells from peripheral blood and use thereof
AU4998100A (en) Methods of using percarboxylic acid or anions thereof and methods of making the same
AU7437900A (en) Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses
AU3978700A (en) Medical use
AU2021601A (en) Composition for the treatment of dandruff
GB9916790D0 (en) Storage of microorganisms,cells and tissue
AU1878201A (en) Composition for the treatment of damaged tissue
AU2001232053A1 (en) System for the extracorporeal treatment of blood
AU2002238218A1 (en) Prolonged storage of red blood cells
AU6219100A (en) The use of membranes, cells and tissue from the area postrema to identify therapeutic compounds
AU3064800A (en) The therapeutic use of r-warfarin as anticoagulant
AU4605500A (en) Medical membrane for stimulating tissue formation
AU5969300A (en) Pressure treatment of cells
AU1043601A (en) Medical use
AU4774200A (en) Long term cell culture of human carcinoma

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase